Vor Biopharma (NASDAQ:VOR) Trading 9.7% Higher – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR) was up 9.7% during mid-day trading on Friday . The stock traded as high as $16.31 and last traded at $16.4150. Approximately 1,309,505 shares changed hands during trading, an increase of 29% from the average daily volume of 1,017,900 shares. The stock had previously closed at $14.97.

More Vor Biopharma News

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: HC Wainwright materially raised forward EPS estimates (Q1–Q4 2026 and FY2026–2029), cutting projected losses for 2026–2028 and now forecasting FY2029 EPS of $4.16; the firm keeps a “Buy” rating and $31 price target — this reduces near‑term downside in forecasts and signals brighter long‑term expectations. HC Wainwright research note
• Neutral Sentiment: Broader Wall Street coverage remains mixed-to-positive: multiple firms have buy/overweight ratings while several maintain holds; the MarketBeat consensus target remains well above the current price, implying analyst upside but with dispersion in conviction. Analyst coverage summary
• Neutral Sentiment: Institutional ownership is high (reported ~97% held by institutions) and some new stakes were disclosed recently; that concentration can amplify moves but also means flow changes (in or out) matter more than usual. Institutional holdings update
• Negative Sentiment: Ra Capital Management, L.P. (a director-level holder) has been an active seller in April, unloading multiple tranches (including >500k shares on Apr 13 and additional sales on Apr 2–15), trimming its position materially — this large insider selling increases supply and is likely weighing on sentiment. SEC Form 4 — Ra Capital sales Coverage of Ra Capital sales

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Jefferies Financial Group began coverage on Vor Biopharma in a research report on Monday, March 30th. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Citigroup began coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright reduced their price objective on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.56.

Vor Biopharma Price Performance

The business’s 50-day moving average price is $14.66 and its two-hundred day moving average price is $16.67. The firm has a market cap of $810.39 million, a price-to-earnings ratio of -0.04 and a beta of 1.92.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 53,644 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $16.01, for a total value of $858,840.44. Following the sale, the director directly owned 3,197,619 shares in the company, valued at approximately $51,193,880.19. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 2,207,379 shares of company stock valued at $36,632,973 over the last quarter. 0.45% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently made changes to their positions in the company. Ariose Capital Management Ltd purchased a new stake in shares of Vor Biopharma in the third quarter worth approximately $5,368,000. Fcpm Iii Services B.V. purchased a new stake in Vor Biopharma in the 3rd quarter worth approximately $18,496,000. Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma in the 4th quarter worth approximately $134,000. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 2nd quarter valued at $66,000. Finally, Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).